Chembio Diagnostics Announces Proposed Public Offering of Common Stock
May 06 2020 - 04:01PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio”),
a leading point-of-care diagnostic company focused on
infectious diseases, announced today a proposed public offering of
an undetermined number of shares of its common stock. All shares of
common stock to be sold in the proposed offering will be offered by
Chembio. In addition, Chembio expects to grant the underwriters a
30-day option to purchase additional shares, in a number equal to
up to 15% of the number of shares of common stock sold in the
proposed offering, at the public offering price less the
underwriting discounts and commissions. The proposed offering is
subject to market and other conditions, as well as customary
closing conditions, and there can be no assurance as to whether or
when the proposed offering may be completed, or as to the size or
other terms thereof.
Chembio intends to use the net proceeds from the
offering to support the refocus of its business strategy, including
the manufacturing and further commercialization of the DPP COVID‑19
System, to expand its sales force to support growth, to increase
its manufacturing capacity and for other general corporate
purposes.
Baird is acting as sole book‑running manager for
the proposed offering. Dougherty & Company LLC is acting as
co-manager for the proposed offering.
The offering is being made pursuant to an
effective shelf registration statement on Form S-3
(No. 333‑227398) previously filed with the U.S. Securities and
Exchange Commission (the “SEC”). The shelf registration statement
and a preliminary prospectus supplement relating to the proposed
offering have been filed with the SEC and are available on the
SEC’s website located at www.sec.gov. Copies of the preliminary
prospectus supplement and accompanying prospectus may also be
obtained by contacting Robert W. Baird & Co. Incorporated,
Attention: Syndicate Department, 777 E. Wisconsin Avenue,
Milwaukee, WI 53202, by telephone at (800) 792-2473 or by email at
syndicate@rwbaird.com. The final terms of the proposed offering
will be disclosed in a final prospectus supplement to be filed with
the SEC.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction.
About Chembio
DiagnosticsChembio is a leading point-of-care diagnostics
company focused on detecting and diagnosing infectious diseases
including COVID-19, sexually transmitted disease and fever and
tropical disease. Chembio’s patented DPP technology platform, which
uses a small drop of blood from the fingertip, provides
high-quality, cost-effective results in approximately 15 minutes.
Coupled with Chembio’s extensive scientific expertise, its novel
DPP technology offers broad market applications beyond infectious
disease. Chembio’s products are sold globally, directly and through
distributors, to hospitals and clinics, physician offices, clinical
laboratories, public health organizations, government agencies, and
consumers. Learn more at www.chembio.com.
DPP is Chembio’s registered trademark. For
convenience, this trademark appears in this release without ®
symbols, but that practice does not mean that Chembio will not
assert, to the fullest extent under applicable law, its rights to
its trademark.
Forward-Looking StatementsThis press release
contains statements, concerning, among other matters, the
anticipated use of net proceeds from the proposed offering, that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
reflect management’s current views based on certain assumptions,
and they involve risks and uncertainties. Actual results, events or
performance may differ materially from the forward-looking
statements due to a number of important factors, and will be
dependent upon a variety of factors, including risks described in
public reports filed by Chembio with the SEC, including under the
caption “Risk Factors” in Chembio’s Annual Report on Form 10‑K for
the fiscal year ended December 31, 2019, as amended, and Chembio’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Chembio undertakes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
Contact:Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2023 to Mar 2024